- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Dasatinib
Dasatinib is an oral tyrosine kinase inhibitor indicated for the treatment of Philadelphia chromosome‑positive chronic myeloid leukemia (CML) in chronic, accelerated, or blast phase in adults with resistance or intolerance to prior therapy including imatinib, newly diagnosed chronic phase CML in adults, and Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL) in adults with resistance or intolerance to prior therapy. Dasatinib inhibits multiple tyrosine kinases, including BCR‑ABL, SRC family kinases, c‑KIT, and PDGFR, blocking the abnormal signalling pathways that drive leukemic cell proliferation and survival. It is a second‑generation BCR‑ABL inhibitor with higher potency than imatinib.
Usual adult dose: For newly diagnosed chronic phase CML, the recommended dose is 100 mg taken orally once daily. For accelerated or blast phase CML and for Ph+ ALL, the dose is 140 mg once daily. The 50 mg tablet is used for dose reductions required by adverse reactions or drug interactions, and for patients who need a lower maintenance dose. Dasatinib may be taken with or without food, in the morning or evening. Tablets must be swallowed whole; they should not be crushed or split. If a dose is missed, the patient should take the next dose at the usual time; two doses must not be taken at the same time. Dose adjustments may be required for myelosuppression, fluid retention, or hepatic impairment. Strong CYP3A4 inhibitors should be avoided if possible; if co‑administration cannot be avoided, a dose reduction may be necessary under specialist supervision.
Dosage form: Film‑coated tablets: 50 mg (white to off‑white, round, biconvex). Other available strengths include 20 mg, 70 mg, 100 mg, and 140 mg. The 50 mg tablet is typically imprinted with the strength and manufacturer code.
Onset of action: Peak plasma concentrations are achieved 0.5 to 3 hours after oral administration. Hematologic response in chronic phase CML may be observed within the first 1 to 3 months of therapy, with cytogenetic and molecular responses developing over 6 to 12 months of continuous treatment.
Duration of action: The elimination half‑life of dasatinib is approximately 3 to 5 hours, but once‑daily dosing maintains adequate inhibition of tyrosine kinase activity over the full 24‑hour interval. The therapeutic effect is sustained with continuous daily treatment; discontinuation can lead to disease recurrence.
Alcohol recommendation: Alcohol should be avoided or strictly limited during treatment with dasatinib. Alcohol may increase the risk of gastrointestinal bleeding and hepatotoxicity, and can exacerbate nausea, vomiting, and myelosuppression. Patients with pre‑existing liver disease or those taking anticoagulants should exercise particular caution.
Most common side effects: Myelosuppression (thrombocytopenia, neutropenia, anemia), fluid retention including pleural effusion, diarrhea, headache, musculoskeletal pain, rash, nausea, fatigue, and dyspnea. Complete blood counts should be monitored regularly, especially during the first few months. Fluid retention can be serious; patients should report new or worsening shortness of breath, swelling, or rapid weight gain. Pulmonary arterial hypertension has been reported and may require discontinuation. Dasatinib can prolong the QT interval; electrocardiograms and electrolytes should be monitored in at‑risk patients. Bleeding events, including gastrointestinal and intracranial hemorrhage, have occurred, particularly in patients with thrombocytopenia or those taking anticoagulants. Hepatotoxicity requires periodic liver function testing. Live vaccines should be avoided during therapy. Women of childbearing potential must use effective contraception during treatment and for at least 30 days after the last dose, as dasatinib may cause fetal harm. Dasatinib is available only by prescription and must be prescribed and supervised by a healthcare professional experienced in oncology or hematology.
Would you like to try Dasatinib without a prescription?
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
